Cannflavin B, a non-psychoactive cannabis compound, improved social behavior and brain function in an autism rat model
Cannflavin B, a non-psychoactive compound from cannabis, normalized social behavior, reduced anxiety-like behavior in females, and corrected brain wave abnormalities in adolescent rats exposed to prenatal valproic acid, a model used to study aspects of autism.
Quick Facts
What This Study Found
Cannflavin B (0.2 mg/kg) was well tolerated and ameliorated most VPA-induced changes. It had anxiolytic-like properties in female VPA rats and normalized sociality in both sexes. Most VPA-induced brain wave abnormalities (spectral power, coherence, theta-gamma coupling) were corrected across prefrontal cortex, cingulate cortex, and hippocampus. Cannflavin B also reduced VPA-induced microglial activation in a sex- and region-specific manner.
Key Numbers
0.2 mg/kg cannflavin B; brain regions assessed: prefrontal cortex, cingulate cortex, hippocampus; measures: oscillatory spectral power, coherence, theta-gamma cross-frequency synchrony, Iba1 microglial marker; sex-specific effects documented
How They Did This
Prenatal VPA exposure rat model of autism. Adolescent rats received cannflavin B (0.2 mg/kg, i.p.) and were assessed for behavioral outcomes (anxiety, sociality), neuronal oscillatory changes across brain regions, and microglial markers. Both in vivo and in vitro experiments were conducted.
Why This Research Matters
No pharmacological treatments currently address the core symptoms of autism. While whole cannabis raises concerns for children and CBD results are inconsistent, cannflavin B offers a new non-psychoactive cannabis-derived compound worth investigating.
The Bigger Picture
This highlights that cannabis contains many potentially therapeutic compounds beyond THC and CBD. Cannflavin B belongs to a class of flavonoids that have been largely overlooked despite anti-inflammatory properties, and this is among the first studies to test it in a neurodevelopmental disorder model.
What This Study Doesn't Tell Us
Animal model of autism has limited translational relevance. Single dose tested. Prenatal VPA model captures some but not all aspects of autism. No human data exists for cannflavin B in autism or any neuropsychiatric condition.
Questions This Raises
- ?What is the mechanism by which cannflavin B normalizes neuronal oscillations?
- ?Would chronic treatment maintain these effects?
- ?Could cannflavin B be combined with behavioral therapies for greater effect?
Trust & Context
- Key Stat:
- Cannflavin B normalized sociality in both sexes and corrected brain wave abnormalities in autism model rats
- Evidence Grade:
- Preliminary: animal study testing a novel compound in a single autism model. Well-designed with multiple outcomes but requires extensive validation.
- Study Age:
- 2026 preclinical publication testing cannflavin B in adolescent rats.
- Original Title:
- Cannflavin B ameliorates behavioural and neuronal systems alterations in adolescent rats exposed to prenatal valproic acid.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 195, 118949 (2026)
- Authors:
- Williams, Olivia O F, Coppolino, Madeleine, Manduca, Joshua D, Demers, Taylor C, Henry-Duru, Paula T, Mueller, Talen C, Soubeyrand, Eric, Perrin, Colby J, Akhtar, Tariq A, Perreault, Melissa L
- Database ID:
- RTHC-08710
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is cannflavin B?
It is a non-psychoactive flavonoid naturally found in the cannabis plant. Unlike THC, it does not produce a high, and unlike CBD, it belongs to a different class of compounds (flavonoids) with distinct anti-inflammatory properties.
Could this help with autism?
In this rat model, cannflavin B improved social behavior and corrected brain wave abnormalities associated with autism-like features. However, animal models have limited relevance to human autism, and no clinical data exists yet.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08710APA
Williams, Olivia O F; Coppolino, Madeleine; Manduca, Joshua D; Demers, Taylor C; Henry-Duru, Paula T; Mueller, Talen C; Soubeyrand, Eric; Perrin, Colby J; Akhtar, Tariq A; Perreault, Melissa L. (2026). Cannflavin B ameliorates behavioural and neuronal systems alterations in adolescent rats exposed to prenatal valproic acid.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 195, 118949. https://doi.org/10.1016/j.biopha.2025.118949
MLA
Williams, Olivia O F, et al. "Cannflavin B ameliorates behavioural and neuronal systems alterations in adolescent rats exposed to prenatal valproic acid.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. https://doi.org/10.1016/j.biopha.2025.118949
RethinkTHC
RethinkTHC Research Database. "Cannflavin B ameliorates behavioural and neuronal systems al..." RTHC-08710. Retrieved from https://rethinkthc.com/research/williams-2026-cannflavin-b-ameliorates-behavioural
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.